Analyst
Global Leader of TAVR
Analyst
Global Leader of Surgical Structural Heart
Equibles does not estimate personal net worth.
Larry Wood is recorded as Analyst at Global Leader of TAVR, CEO at PROCEPT BioRobotics Corp (PRCT) and Analyst at Global Leader of Surgical Structural Heart. Edwards Lifesciences Corp reported in an 8-K filed July 25, 2025 that Larry Wood resigned as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart, effective September 1, 2025. PROCEPT BioRobotics Corp reported in an 8-K filed April 19, 2024 that Larry Wood was appointed new member of the Board, effective April 18, 2024. The proxy statement of PROCEPT BioRobotics Corp reports total compensation of $16,783,853 for Larry Wood in fiscal 2025, including a base salary of $304,830. Larry Wood has spoken on 3 earnings calls across 2 companies, most recently for PROCEPT BioRobotics Corp on November 4, 2025. Those appearances were for PROCEPT BioRobotics Corp (PRCT) and Edwards Lifesciences Corp (EW). PROCEPT BioRobotics Corp is classified in the Medical Devices industry within the Healthcare sector. Other companies whose calls Larry Wood spoke on are classified in the Healthcare sector. Other leadership on record at PROCEPT BioRobotics Corp includes Larry L. Wood (CEO and Board Member), Reza Zadno (CEO), Thomas M. Prescott (Chairman and Board Member) and 7 others.
“On July 21, 2025, Larry L. Wood notified the Board of Directors of Edwards Lifesciences Corporation (the "Company") that he will resign from his position as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart of the Company, effective September 1, 2025, to accept a senior leadership position at another company outside cardiovascular.”
“On April 18, 2024, the Board appointed Mr. Larry Wood as a new member of the Board and as a member of the Audit Committee of the Board, with such appointment effective April 18, 2024.”
“I'm excited to be on the call today to discuss our third quarter results and share some early insights from my first couple of months in the role. First, let's talk about the quarter.”
“As my official start date at PROCEPT is only a few weeks away, I won't be commenting on the quarter or taking any questions. But I am appreciative of the opportunity to speak with all of you today.”
“When it comes to TAVR, there is more initial work needed for a TAVR patient compared to a surgical patient. This includes necessary imaging, such as a CT scan for sizing, and often angiograms to check for coronary disease, which are essential for TAVR case planning.”
Global Leader of TAVR
Analyst
Source not stated
Global Leader of Surgical Structural Heart
Analyst
Source not stated
2024-01-01–2025-04-25
Last confirmed by a filing; no departure on record
Proxy statement
Start not stated–2025-09-01
Medical Devices · Healthcare
CEO
2024-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | PROCEPT BioRobotics Corp (PRCT) | CEO | $304,830 | $16,783,853 |
